Search

Compugen Ltd

Uždarymo kaina

2.58 -0.39

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.46

Max

2.6

Pagrindiniai rodikliai

By Trading Economics

Pajamos

663K

-7M

Pardavimai

426K

2.6M

P/E

Sektoriaus vid.

6.351

57.371

Pelnas, tenkantis vienai akcijai

-0.07

Pelno marža

-269.254

Darbuotojai

75

EBITDA

665K

-7M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+90.84% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-09

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-2.5M

223M

Ankstesnė atidarymo kaina

2.97

Ankstesnė uždarymo kaina

2.58

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-24 22:21; UTC

India's GDP Growth Rate YoY Release on August 31, 2026 Expected to Reflect Strong Economic Performance Amid Global Pressures.

2026-08-24 22:16; UTC

News

A federal court upheld an $83.4 million award against Guardant Health for patent infringement, though shares are trading higher in after-market hours.

2026-08-24 22:16; UTC

ICU Medical Inc shares are higher in after-market hours, maintaining a position above the 20-day moving average and near the one-month range's upper end.

2026-08-24 22:16; UTC

Public Storage shares are higher in after-market trading, reflecting routine activity with typical fluctuations within a narrow range since Monday's close.

2026-08-24 22:16; UTC

News

Kenneth S. Courtis bought $3.2 million in Alpha Metallurgical Resources shares, contributing to modest after-market gains following recent insider purchases.

2026-08-24 22:16; UTC

Allegiant Travel Co shares are higher in after-market trading, despite fluctuations during the session and no specific news to explain the movement.

2026-08-24 22:16; UTC

Research Frontiers Inc. shares are higher in after-market trading, reflecting a notable increase from Monday's close and strong performance relative to recent averages.

2026-08-24 22:16; UTC

Starwood Property Trust Inc. shares are roughly flat in after-market trading, amid broader market conditions following three consecutive lower sessions.

2026-08-24 22:16; UTC

IDEXX Laboratories Inc shares are higher in after-market trading, maintaining gains without significant fluctuations. No specific news was identified to explain the movement.

2026-08-24 22:16; UTC

Eastgroup Properties Inc. shares are higher in after-market trading, though they remain near the lower end of their one-month trading range.

2026-08-24 22:16; UTC

US Physical Therapy Inc shares are lower in after-market trading, remaining near the lower end of their one-month range amid broader market caution.

2026-08-24 22:11; UTC

Capri Holdings Ltd shares rose in after-market trading, continuing a gradual increase despite earlier pulling back from a session high. No specific news was identified.

2026-08-24 22:11; UTC

Japan's July 2026 unemployment rate forecast at 2.5% raises cautious market sentiment amid potential Bank of Japan interest rate hikes and mixed sector performance.

2026-08-24 22:11; UTC

Correlated Moves

Citizens Financial Group shares lower in after-market trading, reflecting broader market declines amid rising oil prices and inflation concerns.

2026-08-24 22:11; UTC

Correlated Moves

Columbia Financial Inc shares are lower in after-market trading, reflecting broader weakness and potential influence from Peoples Financial Services Corp's decline.

2026-08-24 22:06; UTC

SM Energy Co. shares are lower in after-market hours, continuing a four-session trend amid concerns over potential oil supply disruptions from new Iran sanctions.

2026-08-24 22:06; UTC

Arcos Dorados Holdings Inc shares are higher in after-market trading, continuing a trend of five consecutive sessions of gains. No specific news was identified.

2026-08-24 22:06; UTC

News

Peabody Energy shares are lower in after-market hours following a class action lawsuit alleging misleading statements about its Centurion mine operations.

2026-08-24 22:06; UTC

Extreme Networks Inc shares are higher in after-market hours, despite recent declines. No specific news was identified to explain the movement.

2026-08-24 22:06; UTC

Correlated Moves

Westinghouse Air Brake Technologies Corp shares are lower in after-market hours, reflecting broader market sentiment amid concerns over potential sanctions against Iran.

2026-08-24 22:06; UTC

CMS Energy Corp shares are higher in after-market hours, recovering from earlier declines. The stock remains below its 20-day moving average.

2026-08-24 22:06; UTC

Marathon Petroleum shares are higher in after-market trading, recovering from an initial dip amid concerns over new Iran sanctions and rising oil prices.

2026-08-24 22:02; UTC

Group 1 Automotive shares traded lower in after-market hours, continuing a trend below the 20-day moving average amid inflation concerns and Core PCE expectations.

2026-08-24 22:02; UTC

MSC Industrial Direct Co Inc shares declined in after-market trading, positioning the stock below its 20-day moving average and near its one-month range low.

2026-08-24 22:02; UTC

Collegium Pharmaceutical shares advanced in after-market trading, despite being below their 20-day moving average and weaker compared to a month ago.

2026-08-24 22:01; UTC

UMB Financial Corp shares are lower in after-market hours, extending a three-day decline. Market focus remains on inflation and Core PCE Price Index expectations.

2026-08-24 22:01; UTC

Eagle Materials Inc shares declined in after-market trading, remaining below their 20-day moving average and near the lower end of their one-month range.

2026-08-24 22:01; UTC

UniFirst Corp shares are lower in after-market hours, reaching a session low. Broader market focus on inflation may be influencing investor sentiment.

2026-08-24 22:01; UTC

Shares of Credicorp Ltd traded lower in after-market hours, reflecting a decline from earlier highs and remaining below the 20-day moving average.

2026-08-24 22:01; UTC

Jones Lang LaSalle Inc. shares declined in after-market trading, continuing a downward trend since Monday's close despite remaining above the 20-day moving average.

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

90.84% į viršų

12 mėnesių prognozė

Vidutinis 5 USD  90.84%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

2

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
help-icon Live chat